BOXED O
WARNING O
: O
WARNING O
: O
EMBRYO B-OSE_Labeled_AE
- I-OSE_Labeled_AE
FETAL I-OSE_Labeled_AE
TOXICITY I-OSE_Labeled_AE
WARNING O
: O
EMBRYO-FETAL O
TOXICITY O
IMPAVIDO O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
. O

Fetal B-NonOSE_AE
death I-NonOSE_AE
and O
teratogenicity B-NonOSE_AE
occurred O
in O
animals O
administered O
miltefosine O
at O
doses O
lower O
than O
the O
recommended O
human O
dose O
. O

Do O
not O
administer O
IMPAVIDO O
to O
pregnant B-Not_AE_Candidate
women O
. O

Obtain O
a O
serum O
or O
urine O
pregnancy B-NonOSE_AE
test O
in O
females O
of O
reproductive O
potential O
prior O
to O
prescribing O
IMPAVIDO O
. O

Females O
of O
reproductive O
potential O
should O
be O
advised O
to O
use O
effective O
contraception O
during O
IMPAVIDO O
therapy O
and O
for O
5 O
months O
after O
therapy O
[ O
see O
Contraindications O
( O
4.1 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.8 O
) O
and O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
EMBRYO-FETAL O
TOXICITY O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

IMPAVIDO O
may O
cause O
fetal O
harm O
. O

Fetal O
death O
and O
teratogenicity O
, O
occurred O
in O
animals O
administered O
miltefosine O
at O
doses O
lower O
than O
the O
recommended O
human O
dose O
. O

Do O
not O
administer O
IMPAVIDO O
to O
pregnant O
women O
. O

Obtain O
a O
serum O
or O
urine O
pregnancy O
test O
in O
females O
of O
reproductive O
potential O
prior O
to O
prescribing O
IMPAVIDO O
. O

Advise O
females O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
therapy O
and O
for O
5 O
months O
after O
therapy O
( O
4.1 O
, O
5.1 O
, O
8.1 O
, O
8.8 O
, O
13.1 O
) O
. O

